Exceeded Financial Guidance in Q3 2025
Total revenue was $76.3 million and adjusted EBITDA was $12 million, both exceeding guidance.
Technology Revenue Growth
Technology segment revenue increased by 7% year-over-year to $52.1 million.
Operational Cost Savings
Temple University Health System and Entegris Health achieved significant cost savings utilizing Health Catalyst's solutions, with $7.5 million and $30 million saved respectively.
Adjusted Gross Margin Improvement
Total adjusted gross margin increased by approximately 50 basis points year-over-year to 53%.
Strong EBITDA Growth
Adjusted EBITDA in Q3 2025 was $12 million, up 64% compared to Q3 2024.